
Revolutionizing spinal fusion and fracture fixation through advanced biomaterials
PRODUCTS
XERAFUSE
Xerafuse™ is Moroxite’s bone mineral granule, a ceramic that can be impregnated with bone morphogenetic protein-2 (BMP-2) during surgery for successful spinal fusion.
Xerafuse has the potential to replace autograft transplantation with a lower and safer BMP-2 dose than used in available carriers and technology. Xerafuse BMP is in late preclinical stage with clinical studies being planned.
Xerafuse can also be used as a standalone bone substitute and graft extender without BMP-2.
XERAFILL
Xerafill™, a HA/CaS injectable bone substitute used in a novel fixation method to reduce the risk of re-operation in fragility fractures.
Moroxite’s Xerafill is delivered at the interface between metallic screw and the adjacent fragile bone. Studies indicate an immediate improved screw bone anchorage and a reduced risk of late fixation failure and re-operation.
Xerafill is in development phase with ongoing preparations for FDA clearance.
Future development will focus on targeting and activating the bone substitute with a systemic bone active drug, a bisphosphonate, to increase new bone formation.
NEWS AND PUBLICATIONS
ABOUT US
We are dedicated to the development of next generation therapeutics in spinal fusion and fracture fixation. We aim to improve patient quality of life and cut societal cost by eliminating the need for autograft in spinal fusion and decrease surgery failure rates.
Our concepts have been developed over decades and are rooted in frontline bone and joint research. Moroxite was founded by Professors of Orthopedics Lars Lidgren and Magnus Tägil as well as PhD Engineer Deepak Raina of Lund University in Sweden.
Moroxite has a well-established and strong patent position covering all important markets and is continually securing IP rights for its unique technology.

BOARD OF DIRECTORS

Semmy Rülf
Chairman of the Board
Semmy Rülf, Dr. h.c, M.Econ, has an extensive experience in the med-tech and IT industry. As a CEO, he built up the successful IT company, Axis Communications and the medtech company, ProstaLund. He has worked at the Swedish Chamber of Commerce, IFÖ, Facit – Eriksson Information and has been regional director at VisitSweden. Board member at Qlictech and Safeture. Rülf has chaired many successful companies in the life science field like BoneSupport, Dignitana, Vitrolife, Xvivoperfusion and Jolife. Currently Chairman for Lithea AB, UGLK and UGLL and Senior Advisor at Igelösa Life Science.

Ola Erici
Board member
Ola Erici is an experienced industrial executive with over 40 years of experience and is currently serving as a senior advisor and a board member in seven international companies, where of chairman in six. He has previously worked as a CEO at Ferrosan AS and Skånemejerier AB and has also held executive positions within the Tetra Pak Group and Gambro AB.

Anna Gisselsson
Board member
With an extensive experience from the life science sector, and a background in R&D, Business development and internationalisation, Anna is now an investment manager at ALMI Invest. She holds a M.Sc. in chemistry and a Ph.D in biochemistry from Lund University. Anna has previously hels positions at GE Healthcare, Medicon Village, Business Sweden and several start up and scale up companies within biotech and medtech.

Stuart B Goodman
Board member
Dr. Stuart B. Goodman is the Robert L. and Mary Ellenburg Professor and with Tenure in the Department of Orthopaedic Surgery at Stanford University. He holds a courtesy appointment in the Department of Bioengineering. From 1994 to 2002, he served as Chief of Orthopaedic Surgery at Stanford. He received his BSc, MD, and MSc from the University of Toronto and a PhD from Lund University, Sweden. His clinical practice focuses on adult reconstructive surgery, while his research spans joint replacement outcomes, osteonecrosis, juvenile arthritis, inflammation, biomaterials, and musculoskeletal tissue regeneration. Dr. Goodman has authored over 660 peer-reviewed publications and has served on NIH, FDA, and AAOS committees, including as past president of the Society For Biomaterials. He is a fellow of multiple prestigious organizations, including the American Institute for Medical and Biological Engineering and the Orthopaedic Research Society. His awards include the Clemson Award for Basic Research and the 2021 Nicolas Andry Lifetime Achievement Award.

Malin Nilsson
Board member
Malin Nilsson, PhD, is a biomedical engineer and entrepreneur with over 20 years of experience in orthopedic biomaterials and medical devices. She holds a PhD in Medical Science from Lund University and a dual MSc in Materials Engineering from Sweden and France. Malin is the founder and CEO of Inossia AB and BoneTrigger AB, which operates OsteoStrong centers in Sweden. She has led product development, clinical research, and international commercialization at Bone Support AB, contributing to FDA approvals and European launches. Malin also runs LaliT AB, providing consulting in medical devices and innovation. She holds 14 patents, has authored over 30 scientific papers, and serves on several boards.
TEAM

Fredrik Lindberg
CEO
Fredrik Lindberg is an MD, PhD and has previously held positions as the Department Head at the Department of Clinical Pharmacology, Lund University Hospital, Nordic Medical Director at Searle Pharmaceuticals, Co-founder and CEO of BoneSupport AB and CEO of Enzymatica AB and AGB-Pharma AB.

Deepak Raina
CTO and VP
Deepak Raina, PhD, engineer, Erasmus-Mundus India- 4EU scholar. He has previously worked as a research associate at the Indian Institute of Technology, followed by a doctoral education at Lund University. He has published widely in scientific journals and received several nominations for the New Investigator Recognition Award from the Orthopedic Research Society. In 2022, he was a finalist among promising entrepreneurs in Southern Sweden.

Linda Andersson
Director Manufacturing and Supply
Linda Andersson has an MSc in chemistry from Lund University and is an experienced professional with over 18 years of experience in R&D and production roles. Before joining Moroxite F, Linda made significant contributions to the listed company Genovis AB, where she held the position of VP of production. In this role, Linda was responsible for initiating and leading ISO:9001 certification and initiating the start-up of a new production facility as well as managing the production and quality control teams.

Lars Lidgren
Senior Advisor
Lars Lidgren, MD, PhD, is Senior Professor of Orthopaedics at Lund University, Sweden. A pioneer in preventing bone and joint infections, he conducted the first RCT study proving antibiotic prophylaxis in joint replacement. He has authored over 500 publications and supervised 35 PhD students. An independent university analysis in 2014 ranked him #1 in Sweden for most granted med-tech patents. His recent research focuses on new treatments for bone and joint infections and bone repair in fragility fractures. He is founder of Bone Support AB, Safeture AB, Orthocell Ltd, and Scandimed (acquired by Zimmer Biomet).

Fredrik Werner
CFO
Fredrik Werner holds a B.Sc. in Economics from Lund University and has over 30 years of senior executive experience in the life science and medtech sectors, having held key leadership roles as CEO and CFO in both public and private companies with a strong international footprint. His career spans strategic, financial, and operational leadership across Europe, the US, and Asia. He has served in senior roles at companies such as Follicum AB, A1M Pharma, BoneSupport, and Airsonett, where he led business expansion, international market entries, and fundraising initiatives.

Marie Grey
CQA and RA
Marie Grey, PhD, is a seasoned expert in quality assurance and regulatory affairs within the medical device and life science sectors. She holds a PhD in Biochemistry and completed postdoctoral research at Lund University. Marie has led QA/RA functions at companies such as UGLK Science, BiBBInstruments, and Clinical Laserthermia Systems, with deep expertise in MDR, FDA, ISO 13485, and ISO 14971.

Helena Lidgren
Project Manager
Helena Lidgren has a BA in social science in addition to studies in business administration, media science and the English language at Lund University and comparative social work at University of Portsmouth, England. She has prior experience as a coordinator in the private and public sectors and has most recently worked with business development, communication, regulatory issues and project management with an IT and corporate health.

Magnus Tägil
CMO
Magnus Tägil is an MD, PhD, Professor and head of the Orthopedic Research Lab at Lund University. His research focuses on experimental fracture healing. He is an active surgeon and has founded companies like AppInMed, AppInConf and Ryggskolan. He is also a consultant for companies in the implant and pharmaceutical industries.

Anna Szilágyi
Director Design and Development
Anna Szilágyi has a PhD in biochemistry from Lund University and is a highly skilled research and development professional with an extensive experience in the medical device and pharmaceutical industries. Before joining Moroxite F, Anna was the product and process support manager of the listed company Immunovia AB. She has also held positions at Johnson & Johnson, Baxter International and Gambro, AB further honing her expertise in the field.

Apurva Kaul
Administrator and QA Admin
Apurva Kaul, has a master’s degree with specialization in marketing from University of Mumbai, India and has over eight years of experience within marketing, client servicing, business development. Her last position was as a general manager of marketing in Anglian Medal Hunt, a sports management company based in India, and as a senior project manager for a non-profit organization.















